Intravenous iron supplementation may protect against acute mountain sickness: A randomized, double-blinded, placebo-controlled trial

High Altitude Medicine and Biology

Volumn 12, Issue 3, 2011, Pages 265-269

  Talbot, Nick P ^a,b   Smith, Thomas G ^a,c   Privat, Catherine ^d   Nickol, Annabel H ^a,b   Rivera Ch, Maria ^d   León Velarde, Fabiola ^d   Dorrington, Keith L ^a,c   Robbins, Peter A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

Author keywords

acute mountain sickness; High altitude; human; hypoxia inducible factor; iron

Indexed keywords

FERRIC HYDROXIDE SUCROSE; FERRITIN; OXYGEN; SODIUM CHLORIDE;

ADULT; ALTITUDE; ALTITUDE DISEASE; ARTERIAL OXYGEN SATURATION; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; HEMATOCRIT; HUMAN; HUMAN EXPERIMENT; IRON THERAPY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEA LEVEL;

ACUTE DISEASE; ADULT; ALTITUDE SICKNESS; FERRIC COMPOUNDS; FERRITINS; HEMATOCRIT; HUMANS; INJECTIONS, INTRAVENOUS; MALE; OXYGEN; SEVERITY OF ILLNESS INDEX; SUCROSE; YOUNG ADULT;

EID: 80053525195     PISSN: 15270297     EISSN: 15578682     Source Type: Journal    
DOI: 10.1089/ham.2011.1005     Document Type: Article

References (30)

1. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, and Ponikowski P. (2009). Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361:2436-2448.
2. Bailey DM and Davies B. (2001). Acute mountain sickness: Prophylactic benefits of antioxidant vitamin supplementation at high altitude. High Alt Med Biol 2:21-29. (Pubitemid 32390272)
3. Bailey DM, Evans KA, James PE, McEneny J, Young IS, Fall L, Gutowski M, Kewley E, McCord JM, Moller K, and Ainslie PN. (2009a). Altered free radical metabolism in acute mountain sickness: Implications for dynamic cerebral autoregulation and blood-brain barrier function. J Physiol 587:73-85.
4. Bailey DM, Taudorf S, Berg RM, Lundby C, McEneny J, Young IS, Evans KA, James PE. Shore A, Hullin DA, McCord JM, Pedersen BK, and Moller K. (2009b). Increased cerebral output of free radicals during hypoxia: Implications for acute mountain sickness? Am J Physiol 297:R1283-1292.
5. Basnyat B and Murdoch DR. (2003). High-altitude illness. Lancet 361:1967-1974. (Pubitemid 36694589)
6. Bruick RK and McKnight SL. (2001). A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294:1337-1340. (Pubitemid 33063099)
7. Dumont L, Mardirosoff C, and Tramer MR. (2000). Efficacy and harm of pharmacological prevention of acute mountain sickness: Quantitative systematic review. BMJ 321:267-272. (Pubitemid 30487464)
8. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, and Ratcliffe PJ. (2001). C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 107:43-54. (Pubitemid 32972036)
9. Formenti F, Constantin-Teodosiu D, Emmanuel Y, Cheeseman J, Dorrington KL, Edwards LM, Humphreys SM, Lappin TR, McMullin MF, McNamara CJ, Mills W, Murphy JA, O'Connor DF, Percy MJ, Ratcliffe PJ, Smith TG, Treacy M, Frayn KN, Greenhaff PL, Karpe F, Clarke K, and Robbins PA. (2010). Regulation of human metabolism by hypoxia-inducible factor. Proc Natl. Acad Sci USA 107:12722-12727.
10. Grü nig E, Mereles D, Hildebrandt W, Swenson ER, Kubler W, Kuecherer H, and Bä rtsch P. 2000 Stress Doppler echocardiography for identification of susceptibility to high altitude pulmonary edema. J Am.Coll Cardiol 35 980-987.
11. Hackett PH, Rennie D, and Levine HD. (1976). The incidence, importance, and prophylaxis of acute mountain sickness. Lancet 2:1149-1155.
12. Hackett PH and Roach RC. (2001). High-altitude illness. N Engl J Med 345:107-114. (Pubitemid 32634570)
13. Hackett PH, Yarnell PR, Hill R, Reynard K, Heit J, and McCormick J. (1998). High-altitude cerebral edema evaluated with magnetic resonance imaging: Clinical correlation and pathophysiology. JAMA 280:1920-1925. (Pubitemid 28559809)
14. Honigman B, Theis MK, Koziol-McLain J, Roach R, Yip R, Houston C, Moore LG, and Pearce P. (1993). Acute mountain sickness in a general tourist population at moderate altitudes. Ann Intern Med 118:587-592. (Pubitemid 23102692)
15. Hornbein TF. (1962). Evaluation of iron stores as limiting high altitude polycythemia. J Appl Physiol 17:243-245.
16. Kaelin WG, Jr. and Ratcliffe PJ. (2008). Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway. Mol Cell 30:393-402. (Pubitemid 351681994)
17. Kakhlon O and Cabantchik ZI. (2002). The labile iron pool: Characterization, measurement, and participation in cellular processes. Free Radic Biol Med 33:1037-1046.
18. Knowles HJ, Raval RR, Harris AL, and Ratcliffe PJ. (2003). Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res 63:1764-1768. (Pubitemid 36460834)
19. Richalet JP, Souberbielle JC, Antezana AM, Dechaux M, Le Trong JL, Bienvenu A, Daniel F, Blanchot C, and Zittoun J. (1994). Control of erythropoiesis in humans during prolonged exposure to the altitude of 6,542 m. Am J Physiol 266: R756-764.
20. Roach RC, Bä rtsch P. Hackett PH, and Oelz O. (1993). The Lake Louise acute mountain sickness scoring system. In: Hypoxia and Molecular Medicine. JR Sutton, CS Houston, and G Coates, eds. Burlington, VT: Queen City Printers, pp. 272-274.
21. Semenza GL. (2004). O2-regulated gene expression: Transcriptional control of cardiorespiratory physiology by HIF-1. J Appl Physiol 96:1173-1177. (Pubitemid 38248698)
22. Smith TG, Balanos GM, Croft QP, Talbot NP, Dorrington KL, Ratcliffe PJ, and Robbins PA. (2008a). The increase in pulmonary arterial pressure caused by hypoxia depends on iron status. J Physiol 586:5999-6005.
23. Smith TG, Brooks JT, Balanos GM, Lappin TR, Layton DM, Leedham DL, Liu C, Maxwell PH, McMullin MF, McNamara CJ, Percy MJ, Pugh CW, Ratcliffe PJ, Talbot NP, Treacy M, and Robbins PA. (2006). Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology. PLoS Med. 3:e290.
24. Smith TG, Robbins PA, and Ratcliffe PJ. (2008b). The human side of hypoxia-inducible factor. Br J Haematol 141:325-334. (Pubitemid 351521147)
25. Smith TG, Talbot NP, Privat C, Rivera-Ch M, Nickol AH, Ratcliffe PJ, Dorrington KL, Leon-Velarde F, and Robbins PA. (2009). Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: Two randomized controlled trials. JAMA 302:1444-1450.
26. Tay EL, Peset A, Papaphylactou M, Inuzuka R, Alonso-Gonzalez R, Giannakoulas G, Tzifa A, Goletto S, Broberg C, Dimopoulos K, and Gatzoulis MA. (2011). Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome. Int J Cardiol 151:307-312.
27. Tissot van Patot MC, Leadbetter G, Keyes LE, Bendrick-Peart J, Beckey VE, Christians U, and Hackett P. (2005). Greater free plasma VEGF and lower soluble VEGF receptor-1 in acute mountain sickness. J Appl Physiol 98:1626-1629. (Pubitemid 40570769)
28. Wang P, Koehle MS, and Rupert JL. (2009). Genotype at the missense G894T polymorphism (Glu298Asp) in the NOS3 gene is associated with susceptibility to acute mountain sickness. High Alt Med Biol 10:261-267.
29. Wilson MH, Newman S, and Imray CH. (2009). The cerebral effects of ascent to high altitudes. Lancet Neurol 8:175-191.
30. Wu TY, Ding SQ, Liu JL, Yu MT, Jia JH, Chai ZC, Dai RC, Zhang SL, Li BY, Pan L, Liang BZ, Zhao JZ, Qi de T, Su, YF, and Kayser B. (2007). Who should not go high: Chronic disease and work at altitude during construction of the Qinghai-Tibet railroad. High Alt Med Biol 8:88-107. (Pubitemid 47001196)